Live Updates > Live Update Details
2025-09-17 04:24:07
Since the beginning of this year, my country has seen a steady stream of good news in the field of innovative drugs, with dozens of original research and development innovative drugs approved for marketing. However, the journey from research and development to market typically takes a decade or more, navigating numerous hurdles, including laboratory trials, clinical validation involving thousands of patients, and rigorous approval processes. From target discovery to review and approval, the total cost of bringing an innovative drug to market exceeds $1 billion. Data shows that from January to July this year, the National Medical Products Administration (NMPA) approved 50 innovative drugs for marketing, exceeding the 48 approved for the entirety of last year. During the 14th Five-Year Plan period, the NMPA approved a total of 210 innovative drugs, demonstrating accelerating growth. Furthermore, my country leads the world in both its innovative drug pipeline and the number of clinical trial projects, demonstrating strong momentum in pharmaceutical innovation. Concurrently, policies are converging to bridge the "last mile" of access for innovative drugs to hospitals.
